SHENZHEN, China and IRVINE, Calif., March 28, 2011 /PRNewswire/ -- Newtech, Inc., and Masimo Corporation (Nasdaq :MASI ) jointly announced today a new technology integration strategy that will make the Masimo rainbow SET Pulse CO-Oximetry™ technology platform a fundamental offering in Newtech's emergency medical services (EMS) and multiparameter product line-up—providing clinicians with a host of innovative new noninvasive, continuous measurements and patient monitoring capabilities for the immediate detection of potentially life-threatening conditions.
"By incorporating the Masimo rainbow SET technology into our products, we will be able to offer the EMS market in China the most advanced technologies in monitoring EMS patients," said Ganbing Wang, President of Newtech, Inc. "We see huge potential within China's EMS market over the next five years because of strong government investment to upgrade the EMS system and, being an innovative medical device company, we are pleased to partner with Masimo in providing the best technology for our customers to meet not only their current demands, but their future demands as well."
Masimo rainbow SET noninvasive and continuous measurements—like total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and rainbow Acoustic Monitoring™ (RAM™), in addition to the "gold-standard" Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR)—provide detailed physiological data that helps clinicians to more rapidly assess patients and detect adverse conditions earlier. Immediate availability of such detailed clinical intelligence and measurement data enables clinicians to proactively detect and treat the early signs of hemodynamic instability, potentially life-threatening conditions and internal bleeding sooner rather than reacting to late indicators and their deleterious effects.
Newtech's utilization of broadband wireless technologies allows seamless transmission of patient-critical vital sign information over China's Emergency Medical 3G and 4G networks and the internet. This real-time, live streaming of video, audio and vital signs data provides caregivers with the ability to immediately assess and treat their patients, at the point of care or during ambulance transport. Information is transmitted by the multiparameter handheld (NT1D) or NT3C and NT5 ambulance mounted patient monitors, to a base station, which may be either a remote centralized monitoring system or hospital Emergency Department, where caregivers are alerted in advance and may prepare treatment regimens.
Pre-hospital/EMS early interventions have been shown to dramatically reduce "call to needle" or "door to needle" treatment times, especially in rural areas, resulting in lower mortality rates, improved patient outcomes and survival rates. Incorporating Masimo rainbow SET technology expands the clinician's ability to assess and treat the pre-hospital/EMS patient to now include noninvasive monitoring of critical blood constituents such as hemoglobin (SpHb), Pleth Variability Index (PVI), and carboxyhemoglobin (SpCO), so that a caregiver may evaluate and treat for blood loss, anemia, and even suspected carbon monoxide poisoning before the patient has reached the hospital.
Masimo President of Worldwide OEM Business & Business Development, Rick Fishel, stated, "Masimo's mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. Newtech's innovative approach to real-time monitoring of patients—in remote/rural settings, during ambulance transport, at the point of care, or wherever the care setting may be—represents a shared vision to bring technology to the patient rather than the patient to the technology, so that care may begin as early as possible. We are very pleased that Masimo's unique rainbow Pulse CO-Oximetry platform is a key component in Newtech's new patient monitors."
About Newtech, Inc.
Founded in 1998, Newtech, Inc. is one of the fastest growing medical device manufacturers in China. The company designs, manufactures and markets patient monitoring systems with a current emphasis in EMS monitoring systems. Located in Shenzhen, China, the company was certified by the city government as a "Shenzhen High-tech Enterprise" in 2001. It's quality system was certified to ISO13485 by TuV PS in 2002. The company's products are all SFDA cleared for China market, with many also CE marked or FDA cleared for worldwide distribution. Additional information about Shenzhen Newtech. Inc. and its products is available on the company's website: www.sznewtech.com.
Masimo (NASDAQ :MASI ) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Non-invasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care ... by Taking Non-invasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation. All trademarks and registered trademarks are the sole property of their respective companies.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the timing and market availability of Shenzhen Newtech products with Masimo rainbow SET technology, risks related to our assumptions that the integration of Masimo rainbow SET provides advanced noninvasive and continuous measurements and patient monitoring capabilities that have the potential to improve clinical decision-making, outcomes, and patient safety, risks related to our belief that Masimo rainbow SET measurements will enable clinicians to detect potentially life-threatening conditions earlier in all patients and clinical settings, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.